Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 9/20 | 0.59 |
| ▸ | DBF4 | Q9UBU7 | 9/20 | 0.59 |
| ▸ | TRPM8 | Q7Z2W7 | 7/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29627451 | 1.00 | CDC7 (0.59) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL15947327 | 0.86 | CDC7 (0.54) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL12186978 | 0.85 | CDC7 (0.64) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL31534636 | 0.84 | CDC7 (0.57) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL27838195 | 0.84 | CDC7 (0.57) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL28381444 | 0.84 | CDC7 (0.57) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL2009745 | 0.84 | RAB9A (0.59) | KDM4EALDH1A1KMT2A | |
| SCHEMBL19523297 | 0.83 | CDC7 (0.62) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL455876 | 0.83 | CDC7 (0.62) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL8867093 | 0.83 | CDC7 (0.62) | CDC7DBF4TRPM8MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924211-A | Preparation method of febuxostat | 哈药集团技术中心 | 2024-04-26 | — | — | CN | claimed |
| CN-117069675-A | Preparation method of febuxostat | 河北冀衡药业股份有限公司 | 2023-11-17 | — | — | CN | claimed |
| CN-110229117-B | Novel preparation method of febuxostat | 福安药业集团重庆博圣制药有限公司 | 2023-04-18 | — | — | CN | claimed |
| CN-115772137-A | Preparation method of febuxostat | 济宁晟泰药业有限公司 | 2023-03-10 | — | — | CN | claimed |
| CN-109320474-B | Preparation method of febuxostat | 昆明源瑞制药有限公司 | 2021-06-29 | — | — | CN | claimed |
| CN-112961119-A | Preparation method of febuxostat impurity | 廊坊师范学院 | 2021-06-15 | — | — | CN | claimed |
| CN-111110854-A | Composition comprising a histamine release-promoting substance and an inhibitory compound | 黄泳华 | 2020-05-08 | — | — | CN | claimed |
| CN-111039891-A | Method for synthesizing febuxostat and intermediate thereof | 杭州朱养心药业有限公司 | 2020-04-21 | — | — | CN | claimed |
| US-20140112992-A1 | PROCESS FOR FEBUXOSTAT | HETERO RESEARCH FOUNDATION (IN) | 2014-04-24 | — | — | US | claimed |
| EP-2718272-A2 | PROCESS FOR FEBUXOSTAT | Hetero Research Foundation (IN) | 2014-04-16 | — | — | EP | claimed |
| WO-2012168948-A2 | PROCESS FOR FEBUXOSTAT | HETERO RESEARCH FOUNDATION (IN) | 2012-12-13 | — | — | WO | claimed |
| WO-2012131590-A1 | AN IMPROVED PROCESS FOR PREPARATION OF FEBUXOSTAT AND ITS POLYMORPHIC CRYSTALLINE FORM C THEREOF | SANDOZ AG (CH) | 2012-10-04 | — | — | WO | claimed |
| WO-2011141933-A2 | PROCESS FOR PREPARATION OF 2-[3-CYANO-4-(2-METHYLPROPOXY)PHENYL]-4-METHYLTHIAZOLE-5-CARBOXYLIC ACID AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2011-11-17 | — | — | WO | claimed |
| CN-111072591-B | Febuxostat and intermediates and synthesis thereof | 杭州朱养心药业有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-111039891-B | Method for synthesizing febuxostat and intermediate thereof | 杭州朱养心药业有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-110824067-B | Method for detecting genotoxic impurities in febuxostat | 天津药物研究院有限公司 | 2024-12-27 | — | — | CN | disclosed |
| WO-2011141933-A2 | PROCESS FOR PREPARATION OF 2-[3-CYANO-4-(2-METHYLPROPOXY)PHENYL]-4-METHYLTHIAZOLE-5-CARBOXYLIC ACID AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011066803-A1 | PREPARATION METHOD OF INTERMEDIATE OF FEBUXOSTAT | 重庆医药工业研究院有限责任公司 (CN) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011031409-A1 | PROCESSES FOR PREPARING FEBUXOSTAT | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031409-A1 | PROCESSES FOR PREPARING FEBUXOSTAT | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140112992-A1 | PROCESS FOR FEBUXOSTAT | FIP1L1, FH, FIBP | CDC7 4490/4885DBF4 2831/4885TRPM8 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.